Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (11): 1027-1034.DOI: 10.3969/j.issn.1673-8640.2024.11.001
LIANG Liang, YANG Haiqing(), LI Yashan, WANG Jian, MAN Baohua, TANG Haixian, ZHANG Xiaojun, HE Sai, YIN Yan
Received:
2023-07-28
Revised:
2024-07-08
Online:
2024-11-30
Published:
2024-11-29
Contact:
YANG Haiqing
CLC Number:
LIANG Liang, YANG Haiqing, LI Yashan, WANG Jian, MAN Baohua, TANG Haixian, ZHANG Xiaojun, HE Sai, YIN Yan. Clinical roles of miR-21,miR-222,miR-146b and miR-7 in diagnosis of papillary thyroid carcinoma[J]. Laboratory Medicine, 2024, 39(11): 1027-1034.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.11.001
基因名称 | 上游引物(5'~3') | 下游 引物① |
---|---|---|
miR-21 | UAGCUUAUCAGACUGAUGUUGA | 通用 引物 |
miR-146b | UGAGAACUGAAUUCCAUAGGCU | 通用 引物 |
miR-222 | CUCAGUAGCCAGUGUAGAUCCU | 通用 引物 |
miR-7 | UGGAAGACUAGUGAUUUUGUUGU | 通用 引物 |
U6 | GGAACGATACAGAGAAGATTAGC | 通用 引物 |
基因名称 | 上游引物(5'~3') | 下游 引物① |
---|---|---|
miR-21 | UAGCUUAUCAGACUGAUGUUGA | 通用 引物 |
miR-146b | UGAGAACUGAAUUCCAUAGGCU | 通用 引物 |
miR-222 | CUCAGUAGCCAGUGUAGAUCCU | 通用 引物 |
miR-7 | UGGAAGACUAGUGAUUUUGUUGU | 通用 引物 |
U6 | GGAACGATACAGAGAAGATTAGC | 通用 引物 |
组别 | 例数 | miR-21 | miR-146b | miR-222 | miR-7 |
---|---|---|---|---|---|
正常对照组 | 50 | 1.06±0.48 | 1.09±0.40 | 1.05±0.34 | 1.09±0.49 |
良性结节组 | 50 | 2.25±1.40* | 1.96±0.46* | 2.49±0.59* | 0.63±0.23* |
PTC 组 | 150 | 4.12±3.13*# | 2.97±1.12*# | 4.06±2.38*# | 0.39±0.22*# |
F值 | 31.53 | 86.30 | 52.04 | 107.63 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | miR-21 | miR-146b | miR-222 | miR-7 |
---|---|---|---|---|---|
正常对照组 | 50 | 1.06±0.48 | 1.09±0.40 | 1.05±0.34 | 1.09±0.49 |
良性结节组 | 50 | 2.25±1.40* | 1.96±0.46* | 2.49±0.59* | 0.63±0.23* |
PTC 组 | 150 | 4.12±3.13*# | 2.97±1.12*# | 4.06±2.38*# | 0.39±0.22*# |
F值 | 31.53 | 86.30 | 52.04 | 107.63 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
项目 | 例数 | miR-21 | miR-146b | miR-222 | miR-7 |
---|---|---|---|---|---|
性别 | |||||
男 | 50 | 4.53±3.95 | 3.05±1.22 | 4.14±2.23 | 0.39±0.23 |
女 | 100 | 3.92±2.63 | 2.93±1.08 | 4.02±2.47 | 0.39±0.21 |
t值 | 1.110 | 0.615 | 0.309 | -0.029 | |
P值 | 0.269 | 0.540 | 0.758 | 0.977 | |
年龄 | |||||
≥45岁 | 69 | 4.47±3.78 | 3.00±1.08 | 4.18±2.52 | 0.39±0.21 |
<45岁 | 81 | 3.83±2.43 | 2.94±1.17 | 3.95±2.28 | 0.38±0.24 |
t值 | -1.218 | -0.332 | -0.572 | -0.339 | |
P值 | 0.226 | 0.740 | 0.568 | 0.735 | |
肿块大小 | |||||
≥1 cm | 34 | 4.40±2.90 | 3.21±1.47 | 4.59±2.42 | 0.38±0.21 |
<1 cm | 116 | 4.04±3.21 | 2.90±0.99 | 3.90±2.36 | 0.39±0.22 |
t值 | -0.587 | -1.151 | -1.499 | -0.140 | |
P值 | 0.558 | 0.256 | 0.136 | 0.889 | |
淋巴转移 | |||||
有 | 29 | 5.12±4.61 | 3.54±0.99 | 4.66±3.00 | 0.42±0.25 |
无 | 121 | 3.89±2.63 | 2.84±1.45 | 3.91±2.00 | 0.38±0.21 |
t值 | -1.282 | -2.485 | -1.664 | -1.060 | |
P值 | 0.176 | 0.018 | 0.216 | 0.291 | |
肿瘤分期 | |||||
Ⅰ~Ⅱ期 | 130 | 3.97±3.15 | 2.87±0.98 | 3.87±2.28 | 0.39±0.22 |
Ⅲ~Ⅳ期 | 20 | 5.11±2.92 | 3.62±1.70 | 5.31±2.73 | 0.34±0.20 |
t值 | -1.510 | -1.931 | -2.574 | 0.929 | |
P值 | 0.133 | 0.067 | 0.011 | 0.324 |
项目 | 例数 | miR-21 | miR-146b | miR-222 | miR-7 |
---|---|---|---|---|---|
性别 | |||||
男 | 50 | 4.53±3.95 | 3.05±1.22 | 4.14±2.23 | 0.39±0.23 |
女 | 100 | 3.92±2.63 | 2.93±1.08 | 4.02±2.47 | 0.39±0.21 |
t值 | 1.110 | 0.615 | 0.309 | -0.029 | |
P值 | 0.269 | 0.540 | 0.758 | 0.977 | |
年龄 | |||||
≥45岁 | 69 | 4.47±3.78 | 3.00±1.08 | 4.18±2.52 | 0.39±0.21 |
<45岁 | 81 | 3.83±2.43 | 2.94±1.17 | 3.95±2.28 | 0.38±0.24 |
t值 | -1.218 | -0.332 | -0.572 | -0.339 | |
P值 | 0.226 | 0.740 | 0.568 | 0.735 | |
肿块大小 | |||||
≥1 cm | 34 | 4.40±2.90 | 3.21±1.47 | 4.59±2.42 | 0.38±0.21 |
<1 cm | 116 | 4.04±3.21 | 2.90±0.99 | 3.90±2.36 | 0.39±0.22 |
t值 | -0.587 | -1.151 | -1.499 | -0.140 | |
P值 | 0.558 | 0.256 | 0.136 | 0.889 | |
淋巴转移 | |||||
有 | 29 | 5.12±4.61 | 3.54±0.99 | 4.66±3.00 | 0.42±0.25 |
无 | 121 | 3.89±2.63 | 2.84±1.45 | 3.91±2.00 | 0.38±0.21 |
t值 | -1.282 | -2.485 | -1.664 | -1.060 | |
P值 | 0.176 | 0.018 | 0.216 | 0.291 | |
肿瘤分期 | |||||
Ⅰ~Ⅱ期 | 130 | 3.97±3.15 | 2.87±0.98 | 3.87±2.28 | 0.39±0.22 |
Ⅲ~Ⅳ期 | 20 | 5.11±2.92 | 3.62±1.70 | 5.31±2.73 | 0.34±0.20 |
t值 | -1.510 | -1.931 | -2.574 | 0.929 | |
P值 | 0.133 | 0.067 | 0.011 | 0.324 |
项目 | 联合检测方程 | AUC (95%CI①) | 最佳临界值 | 敏感性/ % | 特异性/ % | Youden指数 |
---|---|---|---|---|---|---|
miR-21 | 0.743(0.666~0.821) | 2.491 | 78.0 | 65.3 | 0.433 | |
miR-146b | 0.828(0.770~0.887) | 2.468 | 86.0 | 64.0 | 0.500 | |
miR-222 | 0.708(0.639~0.777) | 3.444 | 98.0 | 53.3 | 0.513 | |
miR-7 | 0.777(0.709~0.846) | 0.437 | 84.0 | 64.7 | 0.487 | |
miR-21+miR-146b | Logit(P)=-6.041+0.536×miR-21+2.421×miR-146b | 0.877(0.826~0.927) | 0.659 | 76.0 | 84.0 | 0.600 |
miR-21+miR-222 | Logit(P)=-2.415+0.506×miR-21+0.670×miR-222 | 0.816(0.756~0.877) | 0.661 | 78.0 | 76.7 | 0.547 |
miR-21+miR-7 | Logit(P)=1.965+0.418×miR-21-4.136×miR-7 | 0.820(0.749~0.891) | 0.723 | 78.0 | 77.3 | 0.553 |
miR-146b+miR-7 | Logit(P)=-1.846+2.185×miR-146b-4.196×miR-7 | 0.889(0.845~0.934) | 0.786 | 92.0 | 74.4 | 0.667 |
miR-222+miR-146b | Logit(P)=-5.948+2.208×miR146-b+0.645×miR-222 | 0.875(0.828~0.923) | 0.865 | 98.0 | 64.0 | 0.620 |
miR-222+miR-7 | Logit(P)=1.284+0.79×miR-222-5.106×miR-7 | 0.850(0.794~0.906) | 0.794 | 88.0 | 67.3 | 0.553 |
miR-21+miR-146b+miR-7 | Logit(P)=-3.839+0.466×miR-21+2.377×miR-146b-3.682×miR-7 | 0.910(0.867~0.953) | 0.680 | 88.0 | 84.7 | 0.727 |
miR-222+miR-21+miR-146b | Logit(P)=-7.753+0.659×miR-222+0.527×miR-21+2.301×miR-146b | 0.912(0.872~0.952) | 0.756 | 92.0 | 81.3 | 0.733 |
miR-222+miR-21+miR-7 | Logit(P)=-0.197+0.794×miR-222+0.409×miR-21-4.525×miR-7 | 0.879(0.825~0.934) | 0.719 | 86.0 | 79.3 | 0.653 |
miR-222+miR-146b+miR-7 | Logit(P)=-3.829+0.781×miR-222+2.143×miR-146b-4.580×miR-7 | 0.917(0.880~0.954) | 0.757 | 96.0 | 82.7 | 0.787 |
miR-21+miR-222+miR-146b+miR-7 | Logit(P)=-5.669+0.455×miR-21+2.276×miR146-b+0.734×miR-222-3.899×miR-7 | 0.933(0.897~0.969) | 0.712 | 94.0 | 86.7 | 0.807 |
项目 | 联合检测方程 | AUC (95%CI①) | 最佳临界值 | 敏感性/ % | 特异性/ % | Youden指数 |
---|---|---|---|---|---|---|
miR-21 | 0.743(0.666~0.821) | 2.491 | 78.0 | 65.3 | 0.433 | |
miR-146b | 0.828(0.770~0.887) | 2.468 | 86.0 | 64.0 | 0.500 | |
miR-222 | 0.708(0.639~0.777) | 3.444 | 98.0 | 53.3 | 0.513 | |
miR-7 | 0.777(0.709~0.846) | 0.437 | 84.0 | 64.7 | 0.487 | |
miR-21+miR-146b | Logit(P)=-6.041+0.536×miR-21+2.421×miR-146b | 0.877(0.826~0.927) | 0.659 | 76.0 | 84.0 | 0.600 |
miR-21+miR-222 | Logit(P)=-2.415+0.506×miR-21+0.670×miR-222 | 0.816(0.756~0.877) | 0.661 | 78.0 | 76.7 | 0.547 |
miR-21+miR-7 | Logit(P)=1.965+0.418×miR-21-4.136×miR-7 | 0.820(0.749~0.891) | 0.723 | 78.0 | 77.3 | 0.553 |
miR-146b+miR-7 | Logit(P)=-1.846+2.185×miR-146b-4.196×miR-7 | 0.889(0.845~0.934) | 0.786 | 92.0 | 74.4 | 0.667 |
miR-222+miR-146b | Logit(P)=-5.948+2.208×miR146-b+0.645×miR-222 | 0.875(0.828~0.923) | 0.865 | 98.0 | 64.0 | 0.620 |
miR-222+miR-7 | Logit(P)=1.284+0.79×miR-222-5.106×miR-7 | 0.850(0.794~0.906) | 0.794 | 88.0 | 67.3 | 0.553 |
miR-21+miR-146b+miR-7 | Logit(P)=-3.839+0.466×miR-21+2.377×miR-146b-3.682×miR-7 | 0.910(0.867~0.953) | 0.680 | 88.0 | 84.7 | 0.727 |
miR-222+miR-21+miR-146b | Logit(P)=-7.753+0.659×miR-222+0.527×miR-21+2.301×miR-146b | 0.912(0.872~0.952) | 0.756 | 92.0 | 81.3 | 0.733 |
miR-222+miR-21+miR-7 | Logit(P)=-0.197+0.794×miR-222+0.409×miR-21-4.525×miR-7 | 0.879(0.825~0.934) | 0.719 | 86.0 | 79.3 | 0.653 |
miR-222+miR-146b+miR-7 | Logit(P)=-3.829+0.781×miR-222+2.143×miR-146b-4.580×miR-7 | 0.917(0.880~0.954) | 0.757 | 96.0 | 82.7 | 0.787 |
miR-21+miR-222+miR-146b+miR-7 | Logit(P)=-5.669+0.455×miR-21+2.276×miR146-b+0.734×miR-222-3.899×miR-7 | 0.933(0.897~0.969) | 0.712 | 94.0 | 86.7 | 0.807 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
miR-222+miR-146b+miR-7 | 0.914(0.874~0.954) | 0.742 | 96.0 | 82.3 | 0.783 |
miR-21+miR-222+miR-146b+miR-7 | 0.925(0.886~0.964) | 0.730 | 96.0 | 84,6 | 0.806 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
miR-222+miR-146b+miR-7 | 0.914(0.874~0.954) | 0.742 | 96.0 | 82.3 | 0.783 |
miR-21+miR-222+miR-146b+miR-7 | 0.925(0.886~0.964) | 0.730 | 96.0 | 84,6 | 0.806 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
miR-222+miR-146b+miR-7 | 0.938(0.869~1.000) | 0.371 | 98.0 | 85.0 | 0.83 |
miR-21+miR-222+miR-146b+miR-7 | 0.992(0.978~1.000) | 0.387 | 98.0 | 95.0 | 0.93 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
miR-222+miR-146b+miR-7 | 0.938(0.869~1.000) | 0.371 | 98.0 | 85.0 | 0.83 |
miR-21+miR-222+miR-146b+miR-7 | 0.992(0.978~1.000) | 0.387 | 98.0 | 95.0 | 0.93 |
[1] | CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J]. Chin Med J(Engl), 2021, 134(7):783-791. |
[2] |
ZHANG D, TAO L, XU N, et al. CircRNA circTIAM1 promotes papillary thyroid cancer progression through the miR-646/HNRNPA1 signaling pathway[J]. Cell Death Discov, 2022, 8(1):21.
DOI PMID |
[3] | PAPAIOANNOU M, CHORTI A G, CHATZIKYRIAKIDOU A, et al. MicroRNAs in papillary thyroid cancer:what is new in diagnosis and treatment[J]. Front Oncol, 2022,11:755097. |
[4] | 马震. 血清miRNAs在甲状腺乳头状癌诊断和预后评估中的研究进展[J]. 疑难病杂志, 2023, 22 (6):661-664. |
[5] | GALUPPINI F, FASSAN M, BERTAZZA L, et al. Programmed cell death 4(PDCD4)as a novel prognostic marker for papillary thyroid carcinoma[J]. Cancer Manag Res, 2019,11:7845-7855. |
[6] | YORUKER E E, TERZIOGLU D, TEKSOZ S, et al. MicroRNA expression profiles in papillary thyroid carcinoma,benign thyroid nodules and healthy controls[J]. J Cancer, 2016, 7(7):803-809. |
[7] | CHOU C K, CHEN R F, CHOU F F, et al. MiR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E)mutation[J]. Thyroid, 2010, 20(5):489-494. |
[8] | 程维刚, 刘九洲, 张海鸽, 等. 甲状腺癌中微小RNA-146b-5p表达上调通过靶向Smad4促进癌细胞增殖[J]. 中华实验外科杂志, 2022, 39(2):257-260. |
[9] | JIA M, SHI Y, LI Z, et al. MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6[J]. Cancer Lett, 2019,443:145-156. |
[10] | ACIBUCU F, DOKMETAS H S, TUTAR Y, et al. Correlations between the expression levels of micro-RNA146b,221,222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers[J]. Exp Clin Endocrinol Diabetes, 2014, 122(3):137-143. |
[11] | MARDENTE S, MARI E, CONSORTI F, et al. HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells[J]. Oncol Rep, 2012, 28(6):2285-2289. |
[12] | 赵鹏新, 张凯丽, 马维远, 等. miRNA-221和miRNA-222 与甲状腺癌侵袭转移的相关性研究[J]. 河北医药, 2018, 40(20):3077-3080. |
[13] | LI H, ZHAO L, ZHANG Z, et al. Roles of microRNA let-7b in papillary thyroid carcinoma by regulating HMGA2[J]. Tumour Biol, 2017, 39(10):1010428317719274. |
[14] |
LI X, LIU R, WANG Z, et al. MicroRNA-7 regulates the proliferation and metastasis of human papillary carcinoma cells by targeting Bcl-2[J]. Am J Transl Res, 2020, 12(9):5772-5780.
PMID |
[15] | RUIZ-POZO V A, CADENA-ULLAURI S, GUEVARA-RAMÍREZ P, et al. Differential microRNA expression for diagnosis and prognosis of papillary thyroid cancer[J]. Front Med(Lausanne), 2023,10:1139362. |
[16] |
CELAKOVSKY P, KOVARIKOVA H, CHROBOK V, et al. MicroRNA deregulation in papillary thyroid cancer and its relationship with BRAF V600E mutation[J]. In Vivo, 2021, 35(1):319-323.
DOI PMID |
[17] | CAMPENNÌ A, AGUENNOUZ M, SIRACUSA M, et al. Thyroid cancer persistence in patients with unreliable thyroglobulin measurement:circulating microRNA as candidate alternative biomarkers[J]. Cancers(Basel), 2022, 14(22):5620. |
[18] |
ABDELFADEIL A O, HALAWA M R, ZAKY I, et al. Serum microRNA-146b expression for malignancy prediction in euthyroid patients with indeterminate thyroid nodules[J]. Egypt J Immunol, 2024, 31(1):40-47.
PMID |
[19] | 秦小静, 范会利, 林旭, 等. microRNA-7-5p在甲状腺乳头状癌中的表达及机制[J]. 实用医学杂志, 2022,(5):565-570. |
[20] | 卢秀波, 贾勐, 刘洋, 等. 微小RNA-21在甲状腺乳头状癌细胞中的作用[J]. 中华实验外科杂志, 2012, 29(10):1981-1982. |
[21] | HUA K, JIN J, ZHANG H, et al. MicroRNA-7 inhibits proliferation,migration and invasion of thyroid papillary cancer cells via targeting CKS2[J]. Int J Oncol, 2016, 49(4):1531-1540. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||